In a 32-week, open-label, two-way cross-over study with patients suffering from moderate-to-severe plaque psoriasis, the antipsoriatic effect of MTX during the remission-induction phase of treatment was influenced by the folate status and was significantly less if combined treatment with MTX plus FA was used irrespective of pre-treatment folate levels.